Lurbinectedin Pricing Basics
Lurbinectedin (brand name Zepzelca) costs about $13,000 per 4 mg vial in the US, with typical dosing for small cell lung cancer (SCLC) at 3.2 mg/m² every 21 days. A full cycle for an average adult (1.8 m² body surface area) runs around $10,500–$12,000, or $40,000–$50,000 monthly before discounts.[1][2]
How It Stacks Up Against Topotecan
Topotecan, the main chemotherapy alternative for relapsed SCLC, is cheaper at $300–$500 per 4 mg vial. Weekly IV dosing costs $2,000–$4,000 per cycle, roughly 70–80% less than lurbinectedin. Oral topotecan capsules run $3,000–$5,000 monthly, still undercutting Zepzelca significantly.[1][3]
Comparison to Immunotherapies Like Atezolizumab
Atezolizumab (Tecentriq), used in frontline SCLC with chemo, costs $13,200–$15,000 per 1200 mg dose every three weeks—similar to lurbinectedin per infusion. Combined regimens exceed $20,000 monthly. Lurbinectedin edges out as slightly less expensive in second-line monotherapy but lacks the frontline approval Tecentriq has.[2][4]
Irinotecan and Bendamustine as Lower-Cost Options
Irinotecan averages $100–$300 per 100 mg vial, with SCLC cycles at $1,500–$3,000—about 75% cheaper than lurbinectedin. Bendamustine, another salvage therapy, costs $4,000–$6,000 per cycle. Both have comparable response rates in trials but shorter progression-free survival.[3][5]
| Drug | Approx. Monthly Cost (US) | Common Use in SCLC |
|------|---------------------------|---------------------|
| Lurbinectedin | $40K–$50K | 2nd-line post-platinum |
| Topotecan (IV) | $8K–$16K | 2nd-line standard |
| Atezolizumab | $40K–$50K | 1st-line combo |
| Irinotecan | $6K–$12K | Salvage/alternative |
| Bendamustine | $16K–$24K | Off-label salvage |
Real-World Costs with Discounts and Access
Net prices drop 30–50% via manufacturer copay cards or 340B programs—lurbinectedin around $20,000–$30,000 monthly for insured patients. Medicare Part B covers most, but out-of-pocket can hit $1,000–$5,000 per cycle without assistance. Generic topotecan keeps patient costs under $500 monthly.[1][6]
Factors Driving Price Differences
Lurbinectedin's orphan drug status and FDA approval in 2020 justify premium pricing over generics like topotecan (patent expired 2000s). No biosimilars yet; patent protection lasts until 2031.[7] Outcomes data shows lurbinectedin extends survival by 2–3 months vs. topotecan in trials, influencing payer preferences.[5]
[1]: Drugs.com - Zepzelca Pricing
[2]: GoodRx - Lurbinectedin Costs
[3]: ASCO Post - SCLC Treatment Costs
[4]: Tecentriq Pricing via GoodRx
[5]: JCO - Lurbinectedin vs Topotecan Trial
[6]: Zepzelca Access Program
[7]: DrugPatentWatch.com - Lurbinectedin Patents